Toward the dual targeting of HER2 and androgen receptor in patients with high-risk, hormone-naive prostate cancer with curative intent

Ended Project Grant Awarded Last action

Award ID
W81XWH2210067
Recipient
Awarding agency
Obligated
$362,100

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Tacoma, WA 98402, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Geneva Foundation was awarded a $362,100 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program to conduct research toward the dual targeting of HER2 and androgen receptor in patients with high-risk, hormone-naive prostate cancer with curative intent. The two-year grant project period runs from June 1, 2022 to May 31, 2024. Through this funding, The Geneva Foundation will perform applied medical research investigating solutions for prostate cancer on the battlefield and for the general public. The Military Medical Research and Development program aims to transform military and civilian health care by supporting innovative biomedical research with the potential for high impact.

Quick answers

Who received award W81XWH2210067?

W81XWH2210067 was awarded to The Geneva Foundation by Medical Command (Department of the Army) on June 1, 2022.

How much is award W81XWH2210067 worth?

$362,100 has been obligated on W81XWH2210067.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login